|
IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing
|
Other
|
FDA
|
NIAID
|
This collaboration will allow the development of in vitro organ on a chip technology for modeling of SARS-CoV-2 infection, identification of biomarkers and transcriptomic and tissue expression imaging by MIBI/CODEX. The data collected from the organ on a chip systems will then be compared to ongoing analysis of human clinical samples and parallel testing in animal models of COVID.
|
|
ICCFASD SBI Working Group for Pregnant and Postpartum People (ISBI-WG)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, ASPE, CDC, CMS, HRSA, IHS, SAMHSA
|
NIAAA
|
This is a special interest working group formed and led by the ICCFASD. The objectives of the ISBI working group are to exchange information and resources, identify gaps and opportunities for improved implementation and research, and expand collaboration and partnerships between federal agencies. The group includes representatives from the ICCFASD and other federal agencies.
|
|
ICCFASD Strategic Planning Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAAA
|
The ICCFASD Strategic Planning Working Group was formed to review the ICCFASD Strategic Plan and make recommendations to the ICCFASD on ICCFASD strategic planning to make the most impact in the next several years. The ICCFASD Strategic Planning Working Group includes representatives from a variety of ICCFASD member agencies. Continued engagement with communities is essential to the ICCFASD. Input has been sought from a range of community partners (e.g., researchers, practitioners, individuals with lived experiences) to ensure that the ICCFASD collaborative partnership and its priorities and objectives address the needs of persons affected by Fetal Alcohol Spectrum Disorders (FASD) and their families and prevention of prenatal alcohol exposure in children.
|
|
Iconic Future Campaign
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
OD/OER
|
|
|
IEEE Reporting Standards for In Vivo Neural Interface Research Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NINDS
|
The Institute of Electrical and Electronics Engineers (IEEE) Reporting Standards for In Vivo Neural Interface Research Working Group aims to improve the transparency, interpretability, reproducibility of in vivo research studies involving neural interface technology and establish rigorous standard experimental methodologies and outcome measures.
|
|
ImmuneChip+ Area of Interest (AOI)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NCATS, NIAID
|
This working group began with BARDA DRIVe and NCATS who developed an Microphsyiological Systems (MPS) AOI resulting in BAA contracts in 2021 for immune chip development. Continuation of these interests include refining more complex MPS that incorporate the ability to study immune responses across multiple tissues. Focus includes medical counter measures against biological, radiological and chemical threats while fostering the development of interoperable systems, biosensor incorporation (TEER etc.) and MPS standardizations.
|
|
IMPACT Collaboratory: Transforming Dementia Care
|
Research Initiative
|
CDC
|
NIA
|
"The mission of the IMbedded Pragmatic Alzheimer's disease (AD) and AD Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is to build the nation’s capacity to conduct pragmatic clinical trials of interventions embedded within health care systems for people living with dementia and their care partners. The IMPACT Collaboratory accomplishes this mission by developing and disseminating best practice research methods; supporting the design and conduct of pragmatic trials, including pilot studies; building investigator capacity through training and knowledge generation; catalyzing collaboration among stakeholders, healthcare providers, and investigators; and ensuring the research includes culturally tailored interventions and people from diverse and under-represented backgrounds."
|
|
Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National "Ending the HIV Epidemic" (EHE) Goals
|
Research Initiative
|
HRSA
|
NIDA, NIMH
|
The National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) collaborated with the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau to develop a research funding opportunity (RFA-MH-20-520 and RFA-MH-20-521) on methods to enhance screening and treatment for mental and substance use disorders in HRSA Ryan White HIV/AIDS Program funded sites through implementation research, in order to advance the goals of the Ending the HIV Epidemic in the U.S. initiative. The research initiative seeks to strengthen the research/service delivery collaboration between NIH grantees and HRSA-funded HIV care sites, with the goal of increasing retention in HIV care and viral suppression through implementation of evidence-based mental disorder and substance use screening, prevention, and treatment. The research initiative was published in 2020. Eight grants were funded through this initiative (6 NIMH grants and 2 NIDA grants). The NIMH maintains ongoing communication with HRSA to discuss progress and outcomes.
|
|
Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group
|
Research Initiative
|
CDC, FDA, OS
|
NCCIH, NCI, NHGRI, NIDA, NLM
|
The overarching workgroup effort is to enhance research initiatives/resource development as an Interagency Agreement (IAA) workgroup members committed to sustain and accelerate translatability of validation analytics and reference datasets using omics and other multi-omics substitutable [SMART] tools, devices, and HL-7 Fast Healthcare Interoperability Resources (FHIR) technologies to support rapid and efficient interoperability with electronic health records and clinical decision support systems. A second goal is to coordinate and plan trans-NIH and Inter-agency meetings, workshops and initiatives with greater efficiency of Institute and Center Operations (ICO) resources and expertise between agencies. Innovative technologies like HL-7 SMART on FHIR have been demonstrated to enhance health information exchange, affordably and accurately. Novel device monitoring using reference standards including, Food and Drug Administration (FDA) Precision and National Institute of Standards and Technology (NIST) nanofabrication, multi-omics and modeling strategies can be integrated to improve validation and standards biosafety, risk monitoring of adverse drug events, food safety, overuse and resistance to antibiotics, and emerging infection. The intent originated in April 2016 with an Initiative planning meeting that is now ongoing for IAA partnered with the Patient-Centered Outcomes Research Institute (PCORI); other IAA collaboratives in progress.
|
|
In Vitro Assessment of Dermal Hypersensitivity: Using Alternative Methods to Predict Skin Sensitization
|
Research Initiative
|
CDC, FDA
|
NIEHS
|
The primary goal of these efforts is to assess the utility of non-animal test methods for predicting human skin sensitization hazard in an expanded chemical space
|